The startup develops a laser vaporization technology that enables rapid molecular analysis of intra-surgical tissue samples, preserving bio-molecules for accurate disease identification. This method provides pathologists and surgeons with real-time insights into cancer type and stage, eliminating intraoperative blind spots.
Funding
$100K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current intraoperative pathology methods often lack the speed and molecular specificity needed for real-time decision-making during surgery. This can lead to incomplete tumor removal or inaccurate staging, potentially requiring additional surgeries or adjuvant therapies.
Solution
This startup offers a laser vaporization technology designed for rapid molecular analysis of tissue samples during surgery. The technology preserves biomolecules, enabling accurate disease identification in real-time. By vaporizing molecules from a small tissue area and analyzing them for biomarkers, the system compares the results against a molecular fingerprint database to identify the disease type and affected area. This provides pathologists and surgeons with detailed insights into cancer type and stage, reducing uncertainty during procedures.
Target Audience
The primary users are pathologists and surgeons who require rapid and accurate molecular information during surgical procedures.
Features
- Laser vaporization technology for rapid tissue analysis
- Preservation of biomolecules during the vaporization process
- Molecular fingerprint database for disease identification
- Real-time biomarker analysis